AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lurasidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4168 | 367514-87-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 14 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.953 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.122 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 4.477 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 37.411 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.290 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.800 | % | High | 1 |
| herg | hERG pIC50 | 5.562 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 23.496 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 246.037 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.270 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC | 20 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.304 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 164.437 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.360 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.371 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.980 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 251.768 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 1.560 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.150 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.800 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 25, 2020 | PMDA | Sumitomo Dainippon Pharma Co., Ltd. | |
| Oct. 28, 2010 | FDA | SUNOVION PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 1310.34 | 19.49 | 257 | 15925 | 3009 | 90609256 |
| Anosognosia | 1278.94 | 19.49 | 255 | 15927 | 3267 | 90608998 |
| Sexual dysfunction | 1251.56 | 19.49 | 264 | 15918 | 4540 | 90607725 |
| Disturbance in social behaviour | 1205.70 | 19.49 | 250 | 15932 | 3938 | 90608327 |
| Metabolic disorder | 1167.38 | 19.49 | 270 | 15912 | 7200 | 90605065 |
| Personality change | 1014.14 | 19.49 | 240 | 15942 | 7081 | 90605184 |
| Dystonia | 977.05 | 19.49 | 276 | 15906 | 16543 | 90595722 |
| Dyskinesia | 947.08 | 19.49 | 323 | 15859 | 36211 | 90576054 |
| Suicide attempt | 906.94 | 19.49 | 380 | 15802 | 75019 | 90537246 |
| Sedation | 900.09 | 19.49 | 334 | 15848 | 47837 | 90564428 |
| Blood glucose increased | 487.18 | 19.49 | 267 | 15915 | 94979 | 90517286 |
| Completed suicide | 436.17 | 19.49 | 289 | 15893 | 144769 | 90467496 |
| Suicidal ideation | 341.80 | 19.49 | 194 | 15988 | 73661 | 90538604 |
| Akathisia | 301.73 | 19.49 | 102 | 16080 | 11057 | 90601208 |
| Tardive dyskinesia | 291.96 | 19.49 | 99 | 16083 | 10831 | 90601434 |
| Mania | 263.48 | 19.49 | 98 | 16084 | 14026 | 90598239 |
| Hyperprolactinaemia | 156.10 | 19.49 | 52 | 16130 | 5381 | 90606884 |
| Insurance issue | 150.88 | 19.49 | 61 | 16121 | 10897 | 90601368 |
| Adverse drug reaction | 144.15 | 19.49 | 138 | 16044 | 116563 | 90495702 |
| Drug ineffective | 137.53 | 19.49 | 547 | 15635 | 1383751 | 89228514 |
| Serotonin syndrome | 137.08 | 19.49 | 85 | 16097 | 37802 | 90574463 |
| Condition aggravated | 131.49 | 19.49 | 312 | 15870 | 595233 | 90017032 |
| Schizophrenia | 120.38 | 19.49 | 57 | 16125 | 14857 | 90597408 |
| Oculogyric crisis | 118.44 | 19.49 | 35 | 16147 | 2444 | 90609821 |
| Personality change due to a general medical condition | 111.21 | 19.49 | 22 | 16160 | 268 | 90611997 |
| Extrapyramidal disorder | 109.63 | 19.49 | 55 | 16127 | 16248 | 90596017 |
| Psychotic symptom | 104.07 | 19.49 | 31 | 16151 | 2225 | 90610040 |
| Delusion | 102.91 | 19.49 | 50 | 16132 | 13790 | 90598475 |
| Blood prolactin increased | 101.26 | 19.49 | 34 | 16148 | 3603 | 90608662 |
| Galactorrhoea | 100.41 | 19.49 | 36 | 16146 | 4636 | 90607629 |
| Hallucination, auditory | 90.42 | 19.49 | 48 | 16134 | 15927 | 90596338 |
| Bipolar disorder | 83.91 | 19.49 | 38 | 16144 | 8947 | 90603318 |
| Confabulation | 74.22 | 19.49 | 16 | 16166 | 304 | 90611961 |
| Depression | 72.11 | 19.49 | 163 | 16019 | 300438 | 90311827 |
| Myocarditis | 71.20 | 19.49 | 39 | 16143 | 13767 | 90598498 |
| Diarrhoea | 69.44 | 19.49 | 41 | 16141 | 939149 | 89673116 |
| Agitation | 65.65 | 19.49 | 70 | 16112 | 67028 | 90545237 |
| Weight increased | 65.46 | 19.49 | 193 | 15989 | 417734 | 90194531 |
| Psychotic disorder | 65.31 | 19.49 | 50 | 16132 | 31180 | 90581085 |
| Joint swelling | 62.72 | 19.49 | 8 | 16174 | 503292 | 90108973 |
| Drug interaction | 61.98 | 19.49 | 146 | 16036 | 276307 | 90335958 |
| Restlessness | 59.40 | 19.49 | 50 | 16132 | 35670 | 90576595 |
| Arthralgia | 56.07 | 19.49 | 35 | 16147 | 778487 | 89833778 |
| Infusion related reaction | 56.07 | 19.49 | 5 | 16177 | 416775 | 90195490 |
| Tremor | 54.58 | 19.49 | 98 | 16084 | 153075 | 90459190 |
| Alopecia | 52.61 | 19.49 | 12 | 16170 | 495059 | 90117206 |
| Persistent genital arousal disorder | 52.19 | 19.49 | 14 | 16168 | 686 | 90611579 |
| Systemic lupus erythematosus | 49.60 | 19.49 | 4 | 16178 | 361892 | 90250373 |
| Somnolence | 48.55 | 19.49 | 112 | 16070 | 208972 | 90403293 |
| Mental disorder | 47.18 | 19.49 | 42 | 16140 | 32276 | 90579989 |
| Therapy cessation | 46.73 | 19.49 | 44 | 16138 | 36317 | 90575948 |
| Rhabdomyolysis | 45.82 | 19.49 | 51 | 16131 | 51205 | 90561060 |
| Distractibility | 45.58 | 19.49 | 12 | 16170 | 547 | 90611718 |
| Infection | 44.50 | 19.49 | 6 | 16176 | 362088 | 90250177 |
| Parkinsonism | 42.05 | 19.49 | 28 | 16154 | 14037 | 90598228 |
| Rheumatoid arthritis | 40.12 | 19.49 | 8 | 16174 | 362606 | 90249659 |
| Pain | 39.33 | 19.49 | 74 | 16108 | 996267 | 89615998 |
| Swelling | 39.19 | 19.49 | 13 | 16169 | 419045 | 90193220 |
| Negative symptoms in schizophrenia | 38.70 | 19.49 | 8 | 16174 | 123 | 90612142 |
| Intentional overdose | 38.60 | 19.49 | 64 | 16118 | 93770 | 90518495 |
| Withdrawal syndrome | 38.42 | 19.49 | 32 | 16150 | 22492 | 90589773 |
| Anxiety | 37.44 | 19.49 | 131 | 16051 | 309641 | 90302624 |
| Treatment noncompliance | 37.13 | 19.49 | 46 | 16136 | 51681 | 90560584 |
| Amenorrhoea | 36.66 | 19.49 | 24 | 16158 | 11698 | 90600567 |
| Depressed mood | 36.60 | 19.49 | 45 | 16137 | 50177 | 90562088 |
| Hepatic enzyme increased | 35.88 | 19.49 | 10 | 16172 | 360726 | 90251539 |
| Off label use | 35.34 | 19.49 | 325 | 15857 | 1101927 | 89510338 |
| Pneumonia | 34.38 | 19.49 | 38 | 16144 | 638021 | 89974244 |
| Nystagmus | 33.40 | 19.49 | 19 | 16163 | 7208 | 90605057 |
| Generalised tonic-clonic seizure | 33.40 | 19.49 | 36 | 16146 | 34867 | 90577398 |
| Mood altered | 32.70 | 19.49 | 26 | 16156 | 17118 | 90595147 |
| Hallucination | 32.68 | 19.49 | 49 | 16133 | 65910 | 90546355 |
| Abdominal discomfort | 32.22 | 19.49 | 23 | 16159 | 477305 | 90134960 |
| Hyperinsulinaemia | 32.08 | 19.49 | 7 | 16175 | 141 | 90612124 |
| Salivary hypersecretion | 31.86 | 19.49 | 20 | 16162 | 9072 | 90603193 |
| Psychomotor retardation | 31.73 | 19.49 | 16 | 16166 | 4773 | 90607492 |
| Anger | 30.97 | 19.49 | 23 | 16159 | 13697 | 90598568 |
| Psychiatric decompensation | 30.87 | 19.49 | 12 | 16170 | 1931 | 90610334 |
| Peripheral swelling | 30.47 | 19.49 | 18 | 16164 | 413088 | 90199177 |
| Toxicity to various agents | 29.95 | 19.49 | 116 | 16066 | 287730 | 90324535 |
| Pericarditis | 29.79 | 19.49 | 6 | 16176 | 270145 | 90342120 |
| Product use issue | 29.52 | 19.49 | 11 | 16171 | 329908 | 90282357 |
| Hyperthermia | 29.52 | 19.49 | 20 | 16162 | 10315 | 90601950 |
| Wheezing | 29.10 | 19.49 | 4 | 16178 | 238076 | 90374189 |
| Peroneal nerve palsy | 28.98 | 19.49 | 16 | 16166 | 5732 | 90606533 |
| Lower respiratory tract infection | 28.85 | 19.49 | 5 | 16177 | 250654 | 90361611 |
| General physical health deterioration | 28.34 | 19.49 | 14 | 16168 | 355101 | 90257164 |
| Catatonia | 28.20 | 19.49 | 16 | 16166 | 6040 | 90606225 |
| Paranoia | 27.72 | 19.49 | 21 | 16161 | 12887 | 90599378 |
| Depressive symptom | 27.44 | 19.49 | 15 | 16167 | 5270 | 90606995 |
| Crying | 27.30 | 19.49 | 28 | 16154 | 25617 | 90586648 |
| Drug ineffective for unapproved indication | 26.79 | 19.49 | 45 | 16137 | 66599 | 90545666 |
| Abdominal pain upper | 26.72 | 19.49 | 13 | 16169 | 332661 | 90279604 |
| Overdose | 26.70 | 19.49 | 75 | 16107 | 157634 | 90454631 |
| Sinusitis | 26.66 | 19.49 | 14 | 16168 | 343074 | 90269191 |
| Anaemia | 26.54 | 19.49 | 15 | 16167 | 352787 | 90259478 |
| Contraindicated product administered | 26.49 | 19.49 | 12 | 16170 | 320127 | 90292138 |
| Blood insulin increased | 25.89 | 19.49 | 6 | 16176 | 160 | 90612105 |
| Dyspnoea | 24.78 | 19.49 | 78 | 16104 | 880877 | 89731388 |
| Metamyelocyte count increased | 24.61 | 19.49 | 6 | 16176 | 200 | 90612065 |
| Bruxism | 24.37 | 19.49 | 13 | 16169 | 4350 | 90607915 |
| Manic symptom | 24.06 | 19.49 | 5 | 16177 | 79 | 90612186 |
| Apnoea | 24.02 | 19.49 | 17 | 16165 | 9397 | 90602868 |
| Fibromyalgia | 23.98 | 19.49 | 4 | 16178 | 206265 | 90406000 |
| Blister | 23.66 | 19.49 | 8 | 16174 | 254990 | 90357275 |
| Activation syndrome | 23.55 | 19.49 | 6 | 16176 | 240 | 90612025 |
| Nasopharyngitis | 23.30 | 19.49 | 23 | 16159 | 407081 | 90205184 |
| Compartment syndrome | 23.10 | 19.49 | 11 | 16171 | 2901 | 90609364 |
| Mental impairment | 22.96 | 19.49 | 21 | 16161 | 16699 | 90595566 |
| Irritability | 22.88 | 19.49 | 30 | 16152 | 35632 | 90576633 |
| Sedation complication | 22.72 | 19.49 | 21 | 16161 | 16923 | 90595342 |
| Drug intolerance | 22.64 | 19.49 | 28 | 16154 | 447563 | 90164702 |
| Pre-existing condition improved | 22.12 | 19.49 | 16 | 16166 | 9153 | 90603112 |
| Cough | 22.10 | 19.49 | 20 | 16162 | 368942 | 90243323 |
| Abdominal pain | 21.91 | 19.49 | 23 | 16159 | 395698 | 90216567 |
| Mental status changes | 21.85 | 19.49 | 33 | 16149 | 44646 | 90567619 |
| Flat affect | 21.76 | 19.49 | 9 | 16173 | 1702 | 90610563 |
| Apathy | 21.61 | 19.49 | 17 | 16165 | 11023 | 90601242 |
| Type 2 diabetes mellitus | 21.41 | 19.49 | 5 | 16177 | 203239 | 90409026 |
| Mobility decreased | 21.37 | 19.49 | 9 | 16173 | 250725 | 90361540 |
| Feeling abnormal | 21.29 | 19.49 | 72 | 16110 | 167163 | 90445102 |
| Aggression | 21.23 | 19.49 | 25 | 16157 | 26643 | 90585622 |
| Intentional self-injury | 20.91 | 19.49 | 26 | 16156 | 29308 | 90582957 |
| Dyspepsia | 20.63 | 19.49 | 5 | 16177 | 198155 | 90414110 |
| Liver injury | 20.53 | 19.49 | 3 | 16179 | 170564 | 90441701 |
| Trismus | 20.48 | 19.49 | 12 | 16170 | 4809 | 90607456 |
| Cognitive disorder | 20.47 | 19.49 | 41 | 16141 | 69366 | 90542899 |
| Myelocyte count increased | 20.43 | 19.49 | 6 | 16176 | 410 | 90611855 |
| Gastric bypass | 20.17 | 19.49 | 9 | 16173 | 2045 | 90610220 |
| Bipolar II disorder | 20.09 | 19.49 | 6 | 16176 | 434 | 90611831 |
| Therapeutic response unexpected | 19.94 | 19.49 | 22 | 16160 | 21858 | 90590407 |
| Pyrexia | 19.61 | 19.49 | 57 | 16125 | 660428 | 89951837 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anosognosia | 350.91 | 26.30 | 71 | 7595 | 973 | 42612696 |
| Blood prolactin abnormal | 320.68 | 26.30 | 66 | 7600 | 989 | 42612680 |
| Disturbance in social behaviour | 280.13 | 26.30 | 65 | 7601 | 1738 | 42611931 |
| Akathisia | 252.83 | 26.30 | 88 | 7578 | 10363 | 42603306 |
| Dystonia | 235.47 | 26.30 | 88 | 7578 | 12702 | 42600967 |
| Metabolic disorder | 230.25 | 26.30 | 68 | 7598 | 4720 | 42608949 |
| Sexual dysfunction | 227.33 | 26.30 | 73 | 7593 | 6702 | 42606967 |
| Sedation | 193.54 | 26.30 | 99 | 7567 | 30376 | 42583293 |
| Dyskinesia | 183.34 | 26.30 | 90 | 7576 | 25300 | 42588369 |
| Personality change | 177.11 | 26.30 | 58 | 7608 | 5661 | 42608008 |
| Mania | 135.65 | 26.30 | 56 | 7610 | 10491 | 42603178 |
| Suicide attempt | 121.51 | 26.30 | 85 | 7581 | 46015 | 42567654 |
| Sedation complication | 112.59 | 26.30 | 35 | 7631 | 2884 | 42610785 |
| Drug ineffective | 109.67 | 26.30 | 302 | 7364 | 629895 | 41983774 |
| Neuroleptic malignant syndrome | 108.66 | 26.30 | 60 | 7606 | 21412 | 42592257 |
| Suicidal ideation | 104.61 | 26.30 | 79 | 7587 | 48082 | 42565587 |
| Hallucination, auditory | 93.42 | 26.30 | 48 | 7618 | 14816 | 42598853 |
| Tardive dyskinesia | 93.22 | 26.30 | 38 | 7628 | 6886 | 42606783 |
| Extrapyramidal disorder | 86.16 | 26.30 | 47 | 7619 | 16365 | 42597304 |
| Blood glucose increased | 79.17 | 26.30 | 81 | 7585 | 73618 | 42540051 |
| Agitation | 78.91 | 26.30 | 76 | 7590 | 64238 | 42549431 |
| Weight increased | 75.61 | 26.30 | 95 | 7571 | 107888 | 42505781 |
| Completed suicide | 64.55 | 26.30 | 83 | 7583 | 96382 | 42517287 |
| Serotonin syndrome | 61.91 | 26.30 | 45 | 7621 | 25800 | 42587869 |
| Psychotic disorder | 57.01 | 26.30 | 45 | 7621 | 29163 | 42584506 |
| Irritability | 54.17 | 26.30 | 43 | 7623 | 28085 | 42585584 |
| Nail bed bleeding | 52.89 | 26.30 | 13 | 7653 | 445 | 42613224 |
| Schizophrenia | 52.02 | 26.30 | 29 | 7637 | 10521 | 42603148 |
| Aggression | 48.21 | 26.30 | 49 | 7617 | 44114 | 42569555 |
| Delusion | 45.50 | 26.30 | 30 | 7636 | 14704 | 42598965 |
| Tremor | 42.16 | 26.30 | 68 | 7598 | 96861 | 42516808 |
| Antipsychotic drug level increased | 41.14 | 26.30 | 19 | 7647 | 4647 | 42609022 |
| Myocarditis | 40.92 | 26.30 | 31 | 7635 | 18907 | 42594762 |
| Restlessness | 40.50 | 26.30 | 37 | 7629 | 29212 | 42584457 |
| Insomnia | 37.24 | 26.30 | 72 | 7594 | 118181 | 42495488 |
| Hypometabolism | 36.16 | 26.30 | 8 | 7658 | 171 | 42613498 |
| Lumbosacral radiculoplexus neuropathy | 35.35 | 26.30 | 7 | 7659 | 85 | 42613584 |
| Blood prolactin increased | 32.25 | 26.30 | 13 | 7653 | 2285 | 42611384 |
| Psychotic symptom | 31.76 | 26.30 | 13 | 7653 | 2377 | 42611292 |
| Depression | 31.68 | 26.30 | 65 | 7601 | 111298 | 42502371 |
| Anxiety | 31.17 | 26.30 | 67 | 7599 | 118493 | 42495176 |
| Hypomania | 31.16 | 26.30 | 13 | 7653 | 2495 | 42611174 |
| Eosinophil count decreased | 29.78 | 26.30 | 14 | 7652 | 3562 | 42610107 |
| Anaemia | 29.72 | 26.30 | 7 | 7659 | 280271 | 42333398 |
| Parasomnia | 28.51 | 26.30 | 8 | 7658 | 461 | 42613208 |
| Paranoia | 28.19 | 26.30 | 22 | 7644 | 14004 | 42599665 |
| Treatment noncompliance | 27.67 | 26.30 | 34 | 7632 | 37638 | 42576031 |
| Therapy partial responder | 27.07 | 26.30 | 25 | 7641 | 19996 | 42593673 |
| Grip strength decreased | 26.69 | 26.30 | 13 | 7653 | 3575 | 42610094 |
| Grandiosity | 26.67 | 26.30 | 7 | 7659 | 313 | 42613356 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anosognosia | 1460.63 | 20.36 | 291 | 19106 | 3783 | 110566119 |
| Blood prolactin abnormal | 1459.95 | 20.36 | 288 | 19109 | 3547 | 110566355 |
| Disturbance in social behaviour | 1339.94 | 20.36 | 281 | 19116 | 4777 | 110565125 |
| Sexual dysfunction | 1283.45 | 20.36 | 298 | 19099 | 8232 | 110561670 |
| Metabolic disorder | 1206.30 | 20.36 | 295 | 19102 | 10215 | 110559687 |
| Personality change | 1087.72 | 20.36 | 274 | 19123 | 10728 | 110559174 |
| Dystonia | 1037.00 | 20.36 | 317 | 19080 | 25488 | 110544414 |
| Dyskinesia | 953.42 | 20.36 | 353 | 19044 | 51093 | 110518809 |
| Sedation | 921.08 | 20.36 | 374 | 19023 | 69309 | 110500593 |
| Suicide attempt | 912.67 | 20.36 | 417 | 18980 | 102977 | 110466925 |
| Blood glucose increased | 495.18 | 20.36 | 301 | 19096 | 132195 | 110437707 |
| Akathisia | 436.37 | 20.36 | 149 | 19248 | 16964 | 110552938 |
| Completed suicide | 434.94 | 20.36 | 351 | 19046 | 242030 | 110327872 |
| Suicidal ideation | 316.63 | 20.36 | 200 | 19197 | 93737 | 110476165 |
| Tardive dyskinesia | 283.87 | 20.36 | 102 | 19295 | 13477 | 110556425 |
| Mania | 251.70 | 20.36 | 105 | 19292 | 20691 | 110549211 |
| Drug ineffective | 233.43 | 20.36 | 686 | 18711 | 1519854 | 109050048 |
| Serotonin syndrome | 184.45 | 20.36 | 120 | 19277 | 59033 | 110510869 |
| Adverse drug reaction | 180.68 | 20.36 | 149 | 19248 | 105410 | 110464492 |
| Schizophrenia | 164.11 | 20.36 | 79 | 19318 | 21747 | 110548155 |
| Insurance issue | 160.84 | 20.36 | 63 | 19334 | 10549 | 110559353 |
| Hyperprolactinaemia | 154.93 | 20.36 | 54 | 19343 | 6521 | 110563381 |
| Hallucination, auditory | 147.05 | 20.36 | 78 | 19319 | 26319 | 110543583 |
| Extrapyramidal disorder | 143.25 | 20.36 | 79 | 19318 | 28788 | 110541114 |
| Condition aggravated | 129.81 | 20.36 | 350 | 19047 | 734486 | 109835416 |
| Psychotic symptom | 123.80 | 20.36 | 40 | 19357 | 3827 | 110566075 |
| Agitation | 101.96 | 20.36 | 112 | 19285 | 112939 | 110456963 |
| Myocarditis | 98.65 | 20.36 | 63 | 19334 | 29992 | 110539910 |
| Personality change due to a general medical condition | 97.90 | 20.36 | 20 | 19377 | 295 | 110569607 |
| Sedation complication | 97.58 | 20.36 | 54 | 19343 | 19801 | 110550101 |
| Delusion | 96.35 | 20.36 | 57 | 19340 | 23698 | 110546204 |
| Neuroleptic malignant syndrome | 96.22 | 20.36 | 65 | 19332 | 33994 | 110535908 |
| Weight increased | 85.31 | 20.36 | 211 | 19186 | 419433 | 110150469 |
| Oculogyric crisis | 84.65 | 20.36 | 30 | 19367 | 3802 | 110566100 |
| Psychotic disorder | 81.08 | 20.36 | 69 | 19328 | 50868 | 110519034 |
| Restlessness | 69.38 | 20.36 | 66 | 19331 | 56193 | 110513709 |
| Diarrhoea | 66.97 | 20.36 | 61 | 19336 | 1139444 | 109430458 |
| Confabulation | 66.74 | 20.36 | 16 | 19381 | 505 | 110569397 |
| Bipolar disorder | 62.88 | 20.36 | 31 | 19366 | 8976 | 110560926 |
| Drug interaction | 58.80 | 20.36 | 207 | 19190 | 499976 | 110069926 |
| Aggression | 55.69 | 20.36 | 60 | 19337 | 59150 | 110510752 |
| Blood prolactin increased | 54.67 | 20.36 | 23 | 19374 | 4619 | 110565283 |
| Anaemia | 53.29 | 20.36 | 15 | 19382 | 547071 | 110022831 |
| Irritability | 53.16 | 20.36 | 53 | 19344 | 47756 | 110522146 |
| Persistent genital arousal disorder | 52.92 | 20.36 | 14 | 19383 | 662 | 110569240 |
| Infusion related reaction | 51.69 | 20.36 | 4 | 19393 | 381158 | 110188744 |
| Mental disorder | 50.68 | 20.36 | 47 | 19350 | 38744 | 110531158 |
| Paranoia | 49.97 | 20.36 | 37 | 19360 | 22337 | 110547565 |
| Intentional overdose | 48.56 | 20.36 | 85 | 19312 | 132416 | 110437486 |
| Tremor | 47.86 | 20.36 | 108 | 19289 | 202124 | 110367778 |
| Depression | 47.79 | 20.36 | 143 | 19254 | 317192 | 110252710 |
| Antipsychotic drug level increased | 45.59 | 20.36 | 23 | 19374 | 6992 | 110562910 |
| Nail bed bleeding | 45.15 | 20.36 | 13 | 19384 | 843 | 110569059 |
| Treatment noncompliance | 44.01 | 20.36 | 59 | 19338 | 72931 | 110496971 |
| Galactorrhoea | 43.69 | 20.36 | 19 | 19378 | 4136 | 110565766 |
| Eosinophil count decreased | 42.87 | 20.36 | 21 | 19376 | 5997 | 110563905 |
| Pneumonia | 42.48 | 20.36 | 55 | 19342 | 876659 | 109693243 |
| Salivary hypersecretion | 41.60 | 20.36 | 30 | 19367 | 17391 | 110552511 |
| Parkinsonism | 41.46 | 20.36 | 33 | 19364 | 22154 | 110547748 |
| Toxicity to various agents | 41.10 | 20.36 | 180 | 19217 | 480375 | 110089527 |
| Withdrawal syndrome | 40.95 | 20.36 | 38 | 19359 | 31342 | 110538560 |
| General physical health deterioration | 38.98 | 20.36 | 13 | 19384 | 425282 | 110144620 |
| Arthralgia | 37.66 | 20.36 | 49 | 19348 | 779583 | 109790319 |
| Alopecia | 37.40 | 20.36 | 9 | 19388 | 364744 | 110205158 |
| Infection | 37.02 | 20.36 | 9 | 19388 | 362191 | 110207711 |
| Drug ineffective for unapproved indication | 36.42 | 20.36 | 65 | 19332 | 102773 | 110467129 |
| Distractibility | 35.83 | 20.36 | 11 | 19386 | 890 | 110569012 |
| Swelling | 35.34 | 20.36 | 9 | 19388 | 351032 | 110218870 |
| Joint swelling | 34.94 | 20.36 | 17 | 19380 | 442828 | 110127074 |
| Negative symptoms in schizophrenia | 34.71 | 20.36 | 8 | 19389 | 212 | 110569690 |
| Bruxism | 34.30 | 20.36 | 17 | 19380 | 4977 | 110564925 |
| Generalised tonic-clonic seizure | 34.19 | 20.36 | 45 | 19352 | 54635 | 110515267 |
| Dyspnoea | 33.71 | 20.36 | 92 | 19305 | 1106780 | 109463122 |
| Systemic lupus erythematosus | 33.56 | 20.36 | 3 | 19394 | 254335 | 110315567 |
| Lumbosacral radiculoplexus neuropathy | 33.50 | 20.36 | 7 | 19390 | 116 | 110569786 |
| Off label use | 32.01 | 20.36 | 402 | 18995 | 1499783 | 109070119 |
| Anxiety | 30.80 | 20.36 | 131 | 19266 | 344947 | 110224955 |
| Peroneal nerve palsy | 30.61 | 20.36 | 18 | 19379 | 7396 | 110562506 |
| Persecutory delusion | 30.60 | 20.36 | 17 | 19380 | 6274 | 110563628 |
| Hypometabolism | 30.43 | 20.36 | 7 | 19390 | 184 | 110569718 |
| Wound | 30.30 | 20.36 | 3 | 19394 | 234434 | 110335468 |
| Abdominal discomfort | 29.75 | 20.36 | 16 | 19381 | 393842 | 110176060 |
| Abdominal pain | 29.39 | 20.36 | 28 | 19369 | 512961 | 110056941 |
| Catatonia | 28.22 | 20.36 | 20 | 19377 | 11280 | 110558622 |
| Abdominal pain upper | 28.15 | 20.36 | 13 | 19384 | 349098 | 110220804 |
| Product use issue | 27.73 | 20.36 | 10 | 19387 | 311685 | 110258217 |
| Hyperinsulinaemia | 27.60 | 20.36 | 7 | 19390 | 280 | 110569622 |
| Psychomotor retardation | 27.23 | 20.36 | 17 | 19380 | 7775 | 110562127 |
| Therapy partial responder | 27.13 | 20.36 | 33 | 19364 | 37028 | 110532874 |
| Suspected suicide | 27.11 | 20.36 | 22 | 19375 | 15177 | 110554725 |
| Nasopharyngitis | 27.01 | 20.36 | 18 | 19379 | 394343 | 110175559 |
| Lower respiratory tract infection | 26.96 | 20.36 | 5 | 19392 | 243101 | 110326801 |
| Wheezing | 26.75 | 20.36 | 6 | 19391 | 255224 | 110314678 |
| Anger | 26.72 | 20.36 | 24 | 19373 | 18983 | 110550919 |
| Mood swings | 26.67 | 20.36 | 26 | 19371 | 22786 | 110547116 |
| Mobility decreased | 26.08 | 20.36 | 5 | 19392 | 237417 | 110332485 |
| Obsessive-compulsive disorder | 25.81 | 20.36 | 16 | 19381 | 7225 | 110562677 |
| Negative thoughts | 25.74 | 20.36 | 10 | 19387 | 1636 | 110568266 |
| Nystagmus | 25.52 | 20.36 | 19 | 19378 | 11558 | 110558344 |
| Intentional self-injury | 25.27 | 20.36 | 32 | 19365 | 37397 | 110532505 |
| Asthenia | 25.12 | 20.36 | 52 | 19345 | 688947 | 109880955 |
| Overdose | 25.06 | 20.36 | 94 | 19303 | 233700 | 110336202 |
| Mental impairment | 24.98 | 20.36 | 25 | 19372 | 22614 | 110547288 |
| Pyrexia | 24.88 | 20.36 | 78 | 19319 | 898187 | 109671715 |
| Tic | 24.31 | 20.36 | 12 | 19385 | 3481 | 110566421 |
| Hepatic enzyme increased | 24.28 | 20.36 | 13 | 19384 | 320879 | 110249023 |
| Sinusitis | 23.99 | 20.36 | 11 | 19386 | 296677 | 110273225 |
| Thrombocytopenia | 23.78 | 20.36 | 16 | 19381 | 348869 | 110221033 |
| Somnolence | 23.57 | 20.36 | 109 | 19288 | 297340 | 110272562 |
| Hypomania | 23.06 | 20.36 | 17 | 19380 | 10193 | 110559709 |
| Grandiosity | 22.73 | 20.36 | 7 | 19390 | 572 | 110569330 |
| Hypertension | 22.65 | 20.36 | 34 | 19363 | 510050 | 110059852 |
| Oedema peripheral | 22.50 | 20.36 | 15 | 19382 | 328645 | 110241257 |
| Social avoidant behaviour | 22.07 | 20.36 | 13 | 19384 | 5356 | 110564546 |
| Osteoarthritis | 21.95 | 20.36 | 3 | 19394 | 182620 | 110387282 |
| Polydipsia psychogenic | 21.69 | 20.36 | 6 | 19391 | 336 | 110569566 |
| Flat affect | 21.69 | 20.36 | 10 | 19387 | 2495 | 110567407 |
| Hallucination | 21.59 | 20.36 | 52 | 19345 | 101380 | 110468522 |
| Drug hypersensitivity | 21.41 | 20.36 | 29 | 19368 | 454061 | 110115841 |
| Depressive symptom | 21.26 | 20.36 | 15 | 19382 | 8399 | 110561503 |
| Cough | 21.25 | 20.36 | 30 | 19367 | 461611 | 110108291 |
| Compartment syndrome | 20.92 | 20.36 | 13 | 19384 | 5897 | 110564005 |
| Hyperthermia | 20.78 | 20.36 | 22 | 19375 | 21250 | 110548652 |
| Parasomnia | 20.76 | 20.36 | 7 | 19390 | 764 | 110569138 |
| Blood insulin increased | 20.68 | 20.36 | 6 | 19391 | 400 | 110569502 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AE05 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
| FDA EPC | N0000175430 | Atypical Antipsychotic |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D058669 | Adrenergic alpha-2 Receptor Antagonists |
| MeSH PA | D058830 | Serotonin 5-HT2 Receptor Antagonists |
| MeSH PA | D065127 | Dopamine D2 Receptor Antagonists |
| CHEBI has role | CHEBI:37887 | adrenergic antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
Related Drugs by ATC class:
N05AE Indole derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Bipolar affective disorder, current episode depression | indication | 191627008 | DOID:3312 |
| Suicidal thoughts | contraindication | 6471006 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Lowered convulsive threshold | contraindication | 19260006 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Dysphagia | contraindication | 40739000 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Hepatic failure | contraindication | 59927004 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Seizure disorder | contraindication | 128613002 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Transient ischemic attack | contraindication | 266257000 | DOID:224 |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Syncope | contraindication | 271594007 | |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Senile dementia with psychosis | contraindication | 371026009 | |
| Cardiovascular event risk | contraindication | 395112001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.38 | Basic |
| pKa2 | 0.27 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.00 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.33 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 9.31 | DRUG LABEL | ||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.97 | DRUG LABEL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.39 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.20 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 8.17 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.69 | IUPHAR | ||||
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.77 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D04820 | KEGG_DRUG |
| 367514-88-3 | SECONDARY_CAS_RN |
| 4030294 | VANDF |
| 4030301 | VANDF |
| CHEBI:70735 | CHEBI |
| CHEMBL1237021 | ChEMBL_ID |
| CHEMBL1615372 | ChEMBL_ID |
| 7461 | IUPHAR_LIGAND_ID |
| DB08815 | DRUGBANK_ID |
| 22IC88528T | UNII |
| 1040027 | RXNORM |
| 177747 | MMSL |
| 27589 | MMSL |
| 365355 | MMSL |
| d07705 | MMSL |
| 013606 | NDDF |
| 013607 | NDDF |
| 703115008 | SNOMEDCT_US |
| 703116009 | SNOMEDCT_US |
| 715585000 | SNOMEDCT_US |
| C2003424 | UMLSCUI |
| D000069056 | MESH_DESCRIPTOR_UI |
| 8247 | INN_ID |
| 213046 | PUBCHEM_CID |
| 22IC88528T | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7355 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 29 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7356 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 29 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7357 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 29 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7358 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 29 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7359 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 29 sections |
| lurasidone hydrochloride | Human Prescription Drug Label | 1 | 0904-7421 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| lurasidone hydrochloride | Human Prescription Drug Label | 1 | 0904-7422 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 28 sections |
| lurasidone hydrochloride | Human Prescription Drug Label | 1 | 0904-7423 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 28 sections |
| lurasidone hydrochloride | Human Prescription Drug Label | 1 | 0904-7424 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 28 sections |
| lurasidone hydrochloride | Human Prescription Drug Label | 1 | 0904-7425 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 28 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-464 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 24 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-465 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 24 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-466 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 24 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-467 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 24 sections |
| Lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-509 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 21 sections |
| Lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-509 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 21 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-737 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 24 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-346 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-346 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-347 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-347 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-348 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-348 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-349 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-349 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-350 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
| lurasidone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-350 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-887 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-888 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-889 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 20 sections |